CAR-T cell therapy has generated immense enthusiasm within the oncology community since the first FDA approval in 2017. Currently, there are six commercially approved CAR-T cell-based therapies, with more on the horizon. Industry experts Tamara Laskowski and Aya Jakobovits attest to the astounding outcomes witnessed in patients, some of whom have remained in remission for a decade after having received a CAR-T infusion. Join us on this podcast episode as we explore the therapeutic potential of CAR-T cells, their path to clinical trials, and their role in providing astonishing outcomes for patients with limited treatment options.